clinical trial · NCT06471361
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL·phase3·completed·n = 31
Generalized Myasthenia GravisZilucoplan
brief summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.
started
Aug 27, 2024
primary completion
Jan 28, 2025
completion
Feb 3, 2025
last updated
Mar 27, 2026
official title
A Multicenter, Open-Label, Outpatient Study to Evaluate the Safe And Effective Use of a Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration by Study Participants With Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol